An FSU team is working to personalize transcranial magnetic stimulation to better treat psychiatric conditions, including PTSD. Currently, TMS dosing is indirect. The clinician determines how much energy it takes to stimulate the motor cortex and then move the TMS coil and applies that dosage strength to the actual target location, the prefrontal cortex, for treatment.
The team has submitted a patent for a technology that will allow researchers to measure what is happening in the prefrontal cortex directly, using TMS in conjunction with functional near infrared spectroscopy. “Over 20 years ago, we looked at adjusting the dose parameters related to age based on MRI scans,” says researcher Frank “Andrew” Kozel. “Based on our prior success, we think that if we enhance the personalization for each individual, we will improve clinical outcomes.”
View Related Expert Profiles: Go to Source
